1. |
郭子光, 熊曼琪, 徐要林, 等. 現代中醫治療學. 第1版. 四川科學技術出版社, 1995: 263-265.
|
2. |
劉曉光, 張巖, 白艷春, 等. 類風濕性關節炎的治療和護理體會. 現代醫藥衛生, 2007, 23(11): 1715-1716.
|
3. |
亞太風濕病學會聯盟. 不可忽視的風濕性關節炎病人開支[EB/OL]. (2009-9-30)[2010-07-23].http://fs.39.net/099/30/1015949.html.
|
4. |
孫麗霞. 類風濕性關節炎治療藥——阿達木單抗(adalimumab). 世界臨床藥物, 2005, (4): 251-253.
|
5. |
Arnett FC, Edworthy SM, Bl och DA, et al. The American Rheumatis m Ass ociati on 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324 .
|
6. |
陳灝珠. 實用內科學 (下冊). 北京: 人民衛生出版社, 2001: 2318-2319 .
|
7. |
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
|
8. |
Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
|
9. |
van de Putte LBA, Rau R, Breedveld FC, et al. Efficacy and safety of fully human anti-tumour necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis, 2003, 62: 1168-77.
|
10. |
van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis, 2004, 63(5): 508-516.
|
11. |
Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med, 2008, 359(8): 810-820.
|
12. |
Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol, 2008, 18(3): 252-262.
|